A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus gardasil® in 9-15-year-old girls

Article English RESTRICTED
Vesikari, Timo; Brodszki, Nicholas; van Damme, Pierre; Diez-Domingo, Javier; Icardi, Giancarlo; Petersen, Lone Kjeld; Tran, Clément; Thomas, Stéphane; Luxembourg, Alain; Baudin, Martine;

<p>BACKGROUND: A 9-valent human papillomavirus (9vHPV) vaccine has been developed to prevent infections and diseases related to HPV 6/11/16/18 [as per the licensed quadrivalent HPV (qHPV) vaccine], as well as 5 additional oncogenic HPV types (HPV 31/33/45/52/58). Compar... View more
Share - Bookmark